-
No.278
https://news.ya…
2021/09/01 05:07
-
No.227
https://news.ya…
2021/08/30 22:39
-
No.119
https://twitter…
2021/08/09 17:25
-
No.433
https://news.ya…
2021/07/30 18:27
-
No.406
https://news.ya…
2021/06/28 05:53
-
No.108
With the SARS-C…
2021/03/09 21:31
With the SARS-CoV-2 vaccine roll-out gathering pace, we are feeling a bit more optimistic at REPROCELL and continue to support global R&D efforts for COVID-19 and many other disease areas. Our scientists in Japan have recently launched a COVID-19 PCR testing service to help reduce the global burden of the pandemic. We also recently completed patient registration for our phase II clinical trial of Stemchymal, which aims to treat spinocerebellar ataxia.
Some other things we have been excited about this quarter include our precision medicine webinar with Fios Genomics and the relaunch of our YouTube channel which you can subscribe to here.
A few more of our start-of-year highlights are listed below:
Launch of personal iPSC production service [press release]
New iPSC biobanks and differentiation services [video]
Precision medicine as a solution for COVID-19 [blog]
New MSC therapy for liver cirrhosis [blog]
Axion Biosystems makes REPROCELL a distributor of its Maestro systems and consumables in India [press release]
Launch of our clinical services newsletter [subscription]
Getting your product to market, smarter and quicker [webinar]
New publication on RNA reprogramming of EPCs to make clinically-relevant iPSCs
Everything you need to know about the REPROCELL iPSC Biobank [blog]
Please let me know if you have any questions about our products and services – and enjoy the rest of your week!
Kindest regards,
Zara -
No.378
https://twitter…
2021/02/25 18:48
-
No.210
https://headlin…
2021/02/25 04:56
-
No.993
https://headlin…
2021/02/22 22:23
-
No.861
https://headlin…
2021/02/04 06:07
https://www3.nh…
2023/02/15 05:35
https://www3.nhk.or.jp/news/html/20230214/amp/k10013980451000.html